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Abstract 
Recent clinical studies have indicated that intra-tumoral gene expression levels of 
5-fluorouracil (5-FU) metabolism-related enzymes may predict the clinical response of 
several cancers to 5-FU-based chemotherapy. However, few studies examining oral squamous 
cell carcinomas (OSCCs) have been reported. In this study, we determined the expression 
levels of 5-FU metabolism-related enzymes like thymidylate synthase (TS), 
dihydropyrimidine dehydrogenase (DPD), thymidine phosphorylate (TP) and orotate 
phosphoribosyl transferase (OPRT) using reverse transcription-polymerase chain reaction 
(RT-PCR) combined with laser capture microdissection (LCM). We also evaluated the 
correlation between the mRNA expressions of these genes and clinico-pathological factors or 
the treatment effects of 5-FU-based chemotherapy combined with radiotherapy in 27 patients 
with OSCC. No significant correlation was observed between the mRNA expression levels of 
any of the examined genes and the T-stage, N-stage, differentiation grade or mode of tumor 
invasion. Although TS and OPRT mRNA were not correlated with the histopathological 
effects and the development of tumor recurrence, DPD and TP mRNA were significantly 
correlated with the histopathological effects and tumor recurrence. A significant positive 
correlation was also observed between the expression of TS and DPD mRNA, but no other 
correlations were observed among the other genes. Our results suggest that the combined 
evaluation of TP and DPD mRNA expression in tumor cells using LCM and RT-PCR may be 
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a useful predictor of the efficacy of 5-FU-based chemotherapy combined with radiotherapy in 
patients with OSCC. 
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1. Introduction 
Squamous cell carcinoma (SCC) of the head and neck accounts for 6% of all cancers 
worldwide. The disease is potentially curable at an early stage, but most patients present with 
locally advanced disease. Various strategies to improve outcomes by coordinating 
chemotherapy with surgery and radiotherapy have been tried. Although the timing of 
chemotherapy has long been a matter of debate, radiotherapy plus concurrent chemotherapy 
(chemoradiotherapy) has become the standard of care for patients with unresectable SCC of 
the head and neck and for organ preservation [1,2]. 
5-Fluorouracil (5-FU) is one of the most widely used chemotherapeutic agents for the 
treatment of head and neck SCCs [3]. 5-FU itself is inactive and must be phosphorylated to 
exert an antitumor effect. Three different pathways for 5-FU phosphorylation exist. 
Thymidine phosphorylase (TP) [4,5], orotate phosphoribosyltransferase (OPRT) [6,7] and 
uridine phosphorylase (UP) [8,9] are the key enzymes in these pathways. 5-FU is 
phosphorylated to 5-fluoro-deoxyuridine (FdUR) by TP [4,5], which is converted to 
5-fluoro-2’-deoxyuridine-5’-monophosphate (FdUMP) by thymidine kinase. FdUMP exerts 
its anticancer activity through the formation of a ternary complex with thymidylate synthase 
(TS) and 5, 10-methylenetetrahydrofolate (MTHF), resulting in the inhibition of TS and the 
blockade of the DNA synthetic process. 5-FU is also phosphorylated to 
5-fluorouridine-monophosphate (FUMP) by OPRT [6,7] and to 5-fluorouridine (FUR), which 
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is subsequently converted to FUMP by UP [8,9]. FUMP is then phosphorylated to 
fluorouridine diphosphate, which can be either converted to FdUMP or phosphorylated to the 
active metabolite fluorouridine triphosphate, which is extensively incorporated into RNA 
(F-RNA), disrupting normal RNA processing and function. Dihydropyrimidine 
dehydrogenase (DPD) is the first and rate-limiting enzyme for the catabolism of 5-FU. In 
summary, 5-FU is detoxified by DPD and activated by TP, OPRT and UP. Therefore, these 
enzyme may affect the efficacy of 5-FU [10,11]. 
Previous clinical studies have indicated that the intra-tumoral expression levels of TS, 
DPD, TP and OPRT genes may predict the clinical response of several cancers to 5-FU-based 
chemotherapy. The relative expression levels of these genes have also been reported to predict 
the survival of patients with advanced diseases. Thus, theoretically, a high amount of TS and 
DPD and a low amount of TP and OPRT in the tumor tissue is expected to be associated with 
a low probability of response to 5-FU and a poor prognosis. In line with this theory, 
retrospective clinical studies have shown that expression levels of 5-FU metabolism-related 
enzymes are associated with a response to 5-FU in several cancers [4-11]. Ichikawa et al. have 
reported that the response rate to a fluoropyrimidine-based protocol was 75% in colorectal 
tumors with low levels of DPD and TS mRNA, and the median survival time was longer in 
patients with these tumors than in patients with tumors with high DPD and TS mRNA levels 
[12]. A few studies examining this phenomenon in head and neck cancers have been reported 
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[5,13-16]. These studies have shown that a low level of DPD mRNA expression is associated 
with a high probability of response to 5-FU, but in each study some differences in the 
correlation between other enzymes and the response to 5-FU or the prognosis existed. 
The expressions of 5-FU metabolism-related enzymes have been analyzed using 
immunohistochemistry and enzyme-linked immunosorbent assays (ELISAs) for proteins or 
quantitative reverse transcription-polymerase chain reaction (RT-PCR) for mRNAs in solid 
tumors. Recently, a laser-captured microdissection (LCM) technique combined with RT-PCR 
was developed and combined with RNA extraction to examine the mRNA levels of 
5-FU-related metabolic enzymes [17,18]. This technique enables the separate analysis of gene 
expression in cancer cells and cancerous stroma. However, few analyses of these enzymes 
using LCM with RT-PCR have been performed, especially in oral SCCs (OSCCs). In this 
study, we evaluated the mRNA expressions of TS, DPD, TP and OPRT using TaqMan PCR 
after using LCM to extract RNA from tumor cells in paraffin-embedded specimens; the 
relations between the expression levels and clinicopathological factors and histopathological 
effects of chemoradiotherapy in OSCCs were then examined. 
 
2. Material and methods 
2.1. Patients 
Twenty-seven patients with OSCC were enrolled in this study. This study was 
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approved by the Institutional Ethical Committee of Kochi Medical School, Kochi University, 
and written informed consent was obtained from all patients. Eligible criteria included the 
followings; (i) primary OSCC in the tongue or floor of the mouth; (ii) patients in whom the 
performance status was evaluated as 0–2 according to the classification described by the 
Eastern Cooperative Oncology Group; (iii) bone marrow function was maintained (leukocyte 
count: 3000/mm2 or more, platelet count: 100 000/mm2 or more); (iv) patients without liver, 
kidney, heart or lung dysfunction; (v) patients without active double cancer at the start of 
treatment who had not undergone radiotherapy in the head and neck region. Eligible patients 
were between the ages of 39 and 90 years (mean, 62.9 years) (Table 1). The primary site of 
the tumor was the tongue in 16 patients and the floor of the mouth in 11 patients. TNM 
staging categories were determined according to the criteria established by the American Joint 
Committee on Cancer and the International Union against Cancer (UICC) [19]. The patients 
were concurrently treated with 5 mg of peplomycin (PEP) 3 times/week intramuscularly, 250 
mg of 5-FU 3 times/week intravenously and 2 Gy of x-rays 5 times/week in the Kochi 
Medical School Hospital. This combined treatment was given to all patients for 3 to 4 weeks 
depending on the grade of stomatitis. Mean doses were 3254 ± 1659 mg, 39.1 ± 10.8 mg and 
39.7 ± 12.6 Gy in 5-FU, PEP and x-rays, respectively. 
After the treatment course, 14 patients exhibited clinically complete response 
although 6 patients developed local recurrence. Notably, 3 of 13 patients who underwent 
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surgery exhibited pathologically complete response, and 5 of 10 patients who exhibited 
pathologically non-lethal effect in the resected specimens had local recurrence. 
2.2. Histopathologic evaluation of biopsied specimens 
The biopsied specimens before the treatment and surgically resected materials after 
the concurrent chemoradiotherapy were fixed in 4% buffered formalin and embedded in 
paraffin.  Thin sections (4 to 5 μm thick) were prepared using the paraffin embedded 
samples, and the sections were stained with hematoxylin-eosin. A histopathologic 
examination was carried out by evaluating the mode of tumor cell invasion according to 
Willen’s classification [i.e., well-defined border (grade 1), cords and less marked border 
(grade 2), groups of cells and no distinct border (grade 3), and diffuse invasion (grade 4)] [20] 
and the grade of differentiation according to the criteria of the World Health Organization 
[21]. 
2.3. Grade of histological degeneration 
The degeneration of the tumor cells was microscopically evaluated on semi-serial 
sections of the surgically extirpated materials. Degeneration was graded according to the 
previously reported Ohboshi-Shimosato’s classification [22]. Briefly, the 4 grades were as 
follows: Grade I, the tumor cells showed no degenerative changes; grade IIA, less than 70% 
of the tumor cells had died; grade IIB, > 70% of the tumor cells showed lethal degenerative 
damage; grade III, only markedly degenerated non-surviving cells were visible; and grade IV, 
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only tumor cell fragments remained. When a tumor of grade III or IV recurred, the degree of 
degeneration was corrected to grade IIB. 
2.4. LCM and real-time RT-PCR 
Ten-micrometer thick sections obtained from identified areas of formalin-fixed 
paraffin-embedded biopsy specimens with the highest tumor cell concentration were mounted 
on uncoated glass slides. Before microdissection, the sections were stained with nuclear fast 
red (American MasterTech Scientific, Lodi, CA). The sections of interest were selectively 
isolated using laser-captured microdissection (PALM Microsystem; Leica, Wetzler, Germany) 
according to standard procedures. The dissected particles of tissues were transferred to a 
reaction tube containing 400 μL of RNA lysis buffer. 
The samples were homogenized and heated at 92°C for 30 min. Fifty microliters of 2 
M sodium acetate, pH 4.0, was added followed by 600 μL of freshly prepared 
phenol/chloroform/isoamylalcohol (250:50:1). The tubes were placed on ice for 15 min and 
then centrifuged at 13000 rpm for 8 min in a chilled centrifuge. The upper aqueous phase was 
then carefully removed. Glycogen (10 μL) and 300 μL of isopropanol were added. The tubes 
were chilled at –20°C for 30 min to precipitate the RNA. The samples were washed in 500 μL 
of 75% ethanol and air-dried for 15 min. The pellet was resuspended in 50 μL of 5 mM Tris 
buffer. Finally, cDNA was prepared as described by Lord and colleagues [23]. 
Quantification of the four genes of interest and an internal reference gene (β-actin) 
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was performed using a fluorescence-based real-time detection method (ABI PRISM 7900 
Sequence Detection System TaqMan®; Perkin-Elmer Applied Biosystems, Foster City, CA) 
using the standard curve method. The PCR reaction mixture consisted of 1200 nM of each 
primer, 200 nM of probe, 0.4 U of AmpliTaq gold polymerase, 200 nM each of dNTP, 3.5 
mM of MgCl2 and 1 × TaqMan buffer A containing a reference dye. The final volume of the 
reaction mixture was 20 μL. The cycling conditions were 50°C for 2 min and 95°C for 10 min, 
followed by 46 cycles of 95°C for 15 sec and 60°C for 1 min. The gene expression values 
(relative mRNA levels) were expressed as ratios (differences between Ct values) between the 
gene of interest and an internal reference gene (β-actin). Real-time RT-PCR was performed in 
a single run. 
2.5. Statistical analysis 
In Table 2, results are expressed as the mean ± SEM. To evaluate correlations 
between the expression of these genes and the response to chemotherapy, the Student t-test 
was applied. A Spearman correlation analysis was used to evaluate correlations among the 
expressions of the four genes. P value of less than 0.05 was considered statistically significant. 
Cut-off values were determined through analysis of the receiver operating characteristic 
curve. 
 
3. Results 
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3.1. Levels of TS, DPD, TP and OPRT mRNA are not correlated with T stage, N stage, 
differentiation grade or mode of invasion 
The expression levels of TS, DPD, TP and OPRT mRNA in each group classified 
according to T stage, N stage, differentiation grade and mode of invasion are summarized in 
Table 2. No correlations between the mRNA expression levels of 5-FU metabolism-related 
enzyme genes and clinico-pathologic factors like the T and N stage classifications, the 
differentiation grade, and the mode of invasion were observed. 
3.2. Histopathological effect of chemoradiotherapy is correlated with DPD and TP mRNA 
levels, but not with TS and OPRT mRNA levels 
First, we assessed the relation between histopathological effects and tumor sites and 
doses of chemotherapeutic drugs and radiation. However, histopathological effects were not 
correlated with tumor sites and doses of chemotherapeutic drugs and radiation (data not 
shown). Next, we evaluated the relation between histopathological effects and mRNA levels 
of 5-FU metabolism-related enzymes. The mean level of DPD mRNA in OSCCs with lethal 
histopathological effects (≥ grade III) was significantly lower than that in OSCCs with 
nonlethal histopathological effects (≤ grade IIB) (Fig. 1, p=0.0053, cut-off value=1.3). In 
contrast, the mean level of TP mRNA in OSCCs with lethal histopathological effects was 
significantly higher than that in OSCCs with nonlethal histopathological effects (p=0.0218, 
cut-off value=4.3). No correlations between the histopathological effects and the levels of TS 
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or OPRT mRNA were observed. A lethal histopathological effect was obtained in all cases 
with a DPD mRNA level of less than 1.8 and a TP mRNA level of more than 3.0. 
3.3. Local recurrence is correlated with mRNA levels of DPD and TP, but not with mRNA 
levels of TS and OPRT 
As shown in Fig. 2, significant correlations were observed between local recurrence 
and the levels of DPD (p=0.0488, cut-off value=2.0) and TP (p=0.0465, cut off value=3.7). 
The mean level of DPD mRNA in cases with local recurrence was significantly higher than 
that in cases without local recurrence. In contrast, the mean level of TS mRNA in cases with 
local recurrence was significantly lower than that in cases without local recurrence. No 
differences in the mean levels of TS and OPRT mRNA were noted between cases with and 
those without local recurrence. Almost all the cases without local recurrence had low levels of 
DPD mRNA and high levels of TP mRNA. 
3.4. Level of TS mRNA is correlated with level of DPD mRNA but not with levels of TP and 
OPRT mRNA  
Using a Spearman correlation analysis, a significant correlation was observed 
between the TS and DPD mRNA levels (r=0.627, p=0.0005) but not with the TP and OPRT 
mRNA levels (Fig. 3). No correlations among the mRNA levels of DPD, TP and OPRT were 
observed. 
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4. Discussion 
5-FU metabolism-related enzymes like TS, DPD, TP and OPRTP are reported to be 
predictive markers for 5-FU sensitivity in several cancers [4-11,13-16]. In some cancers, 
including oral cancers, however, it is still controversial whether these enzymes predict the 
clinical response to 5-FU-based chemotherapy. One possible reason for the difficulty in 
finding predicting factors is the histological variety in biopsied specimens, which sometimes 
contain large amounts of cancerous stroma. The activity of 5-FU metabolism-related enzymes 
in cancer cells and cancerous stroma is considered to be different, and TS and TP mRNA 
expressions have been reported to be higher in cancer cells than in cancerous stroma, although 
DPD gene expression was lower in cancer cells than in cancerous stroma [24]. Almost all 
previous reports concerning these enzymes have discussed results that were obtained using 
ELISA, immunohistochemistry and RT-PCR without LCM. The surrounding normal tissues 
and cancerous stroma can become contaminated in methods such as ELISA and RT-PCR 
without LCM. In immunohistochemistry, furthermore, the preservation method used to 
prepare the tissue samples and the sensitivity of the antibody being used affect the results. 
Recently, LCM has been developed as a sophisticated method to quantify the mRNA levels of 
these enzymes in cancer cells [17,18,24], which are selectively harvested from target cells in 
paraffin-embedded specimens. In this study, we quantified the mRNA expression levels of TS, 
DPD, TP and OPRT in paraffin-embedded specimens of OSCCs using a method consisting of 
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LCM and RT-PCR and then evaluated the correlations between the mRNA expressions of 
these enzymes and clinicopathological factors or treatment effects. 
The relationships between the mRNA expression levels of the above-mentioned 
enzymes and clinicopathological factors, such as the T-stage, the N-stage, lymph node 
metastasis, the differentiation degree and the invasion mode of the tumor, have been 
previously reported [25,26]. In gastric cancers, TS gene expression was reportedly higher in 
differentiated cases than in undifferentiated cases, although DPD gene expression in the 
undifferentiated cases was higher than that in the differentiated-type cases [27]. Because the 
labeling index of [3H]-thymine in differentiated gastric cancer cells is higher than that in 
undifferentiated cancer cells [28], a synthesis enzyme (e.g., TS) is thought to be facilitated, 
whereas a degradation enzyme (e.g., DPD) is inhibited in differentiated-type cases. However, 
DPD expression in well-differentiated OSCCs is reportedly significantly higher than that in 
moderate and poorly differentiated OSCCs, and no correlation exists between the 
Ki-67-labeling index and DPD expression [29]. In this study, the expression of the enzymes 
was not correlated with T-stage, N-stage, the differentiated grade or the mode of invasion. 
Because the T-stage, N-stage and mode of invasion closely depend on the interaction between 
tumor cells and mesenchymal cells, the obtained results seem reasonable. Further studies are 
needed to determine whether cell proliferation is related to the mRNA expressions of these 
enzymes. 
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In OSCCs, TS expression, but not TS, DPD or OPRT expression, was shown to 
predict the response to S-1 [30]. Kobayashi et al. reported that DPD expression may provide a 
clue to predicting the sensitivity to 5-FU in patients with OSCC [29]. In the present study, the 
DPD mRNA levels in patients with histopathological effects of grade III or IV were 
significantly lower than those in patients with histopathological effects less than grade IIB. 
On the other hand, the TP mRNA levels in patients with histopathological effects more than 
grade III were significantly higher than those in the patients with histopathological effects less 
than grade IIB. Further, a lethal histopathological effect was obtained in all of the cases with a 
DPD mRNA level of less than 1.8 and a TP mRNA level of more than 3.0. Furthermore, DPD 
mRNA expression in the recurrence group was significantly higher than that in the no 
recurrence group, whereas TP mRNA expression in the recurrence group was significantly 
lower than that in the no recurrence group. However, correlations between the 
histopathological effects and the TS or OPRT mRNA levels were not detected. These results 
suggest that the combined evaluation of the DPD and TP mRNA levels in tumor cells may 
predict the clinical effect of 5-FU-based chemotherapy combined with radiotherapy in 
OSCCs. 
Our neoadjuvant therapy consists of radiotherapy and chemotherapy with 5-FU and 
PEP. Kocakova et al. reported that responders to preoperative radiotherapy and concomitant 
capecitabine treatment exhibited a significantly higher expression of TP mRNA than 
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non-responders among patients with rectal carcinoma [31]. Liersch et al. also showed that all 
of their patients who developed cancer recurrence after 5-FU-based chemoradiotherapy had a 
significantly higher TS gene expression level than those patients without recurrences among 
patients with rectal cancer [32]. Thus, the activity of 5-FU metabolism-related enzymes seems 
to affect the efficacy of 5-FU-based chemoradiotherapy. 
In the present study, a significant positive correlation was observed between TS and 
DPD mRNA expressions, but not among other genes. A correlation between TP and DPD 
mRNA expression, as well as between OPRT and TS mRNA expression, was reportedly 
observed in gastric cancer [33], while a correlation between TP and TS mRNA expression was 
reportedly observed in oropharyngeal cancer [5]. Although these results were also obtained 
using LCM combined with RT-PCR, our results differed substantially from the results of these 
previous reports. TS is an enzyme for the de novo synthesis of deoxythymidine 
monophosphate, and DPD is the rate-limiting enzyme in the degradation of pyrimidine bases 
as well as being the key enzyme in the degradation of 5-FU. Our results suggest that cancer 
cells with high TS activity also possess high DPD activity to maintain the homeostasis of 
nucleotide metabolism. The precise mechanism responsible for the correlation between TS 
and DPD is presently unknown, and further studies on this topic are needed. 
The addition of chemotherapy to radiotherapy has recently become the standard of 
care for organ preservation. To improve the clinical benefit of combined therapies at an 
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acceptable level of toxicity, useful predictors for the clinical response of the combined therapy 
must be identified. Our results suggest that the combined evaluation of TP and DPD mRNA 
expression levels in tumor cells using LCM and RT-PCR may be a useful predictor of the 
efficacy of 5-FU-based chemotherapy combined with radiotherapy in patients with OSCC. 
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Table 1. Relation of expression levels of TS, DPD, TP, and OPRT with each stage of carcinomas, differentiation grade and mode of invasion. 
T stage N stage 
Site No. of cases 
T1 T2 T3 T4 
 
N0 ≥N1 
Tongue 16 0 9 5 2   12 4 
Floor of the mouth 11 1 5 1 4   6 5 
Total 27 1 14 6 6   18 9 
Age: 62.9 ± 13.8 (39 – 90), Radiation: 39.7 ± 12.6 Gy, 5-FU: 3254 ± 1659mg, PEP: 39.1 ± 10.8mg 
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Table 2. mRNA levels of four enzymes stratified according to the T-stage, N-stage, differentiation grade and mode of invasion.  
    TS DPD TP OPRT 
T stage T1 (n=1) 0.79 2.08 4.96 0.84 
 T2 (n=14) 2.56 ± 2.00 2.22 ± 2.38 4.01 ± 2.23 1.46 ± 0.74 
 T3 (n=6) 2.67 ± 2.18 1.36 ± 0.66 4.79 ± 2.45 2.70 ± 1.78 
 T4 (n=6) 2.08 ± 1.21 1.89 ± 0.94 3.54 ± 2.04 2.44 ± 1.83 
N stage N0 (n=18) 1.99 ± 1.32 1.68 ± 0.94 4.57 ± 1.92 1.82 ± 1.50 
 ≥N1 (n=9) 3.24 ± 2.46 2.49 ± 2.84 3.20 ± 2.42 2.16 ± 1.15 
Differentiation grade Low (n=1) 7.61 9.87 1.61 1.19 
  Moderate (n=9) 2.35 ± 1.62 1.70 ± 1.00 3.42 ± 2.60 2.28 ± 1.64 
  High (n=17) 2.13 ± 1.54 1.62 ± 0.81 4.63 ± 1.80 1.79 ± 1.27 
Mode of invasion Grade 2 (n=1) 0.79 2.08 4.96 0.84 
 Grade 3 (n=13) 2.50 ± 1.42 1.89 ± 1.03 4.93 ± 2.12 2.10 ± 1.21 
 Grade 4 (n=13) 2.45 ± 2.24 2.01 ± 2.43 3.24 ± 2.00 1.85 ± 1.58 
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Figure legends 
Figure 1. The mRNA levels of DPD and TP but not TS and OPRT mRNA levels are 
significantly associated with histopathological effects. The mRNA levels of the four enzymes 
are stratified according to the histopathological effects. The mRNA expression levels of TP 
and DPD are plotted according to the histopathological effects. 
 
Figure 2. The mRNA levels of DPD and TP but not TS and OPRT mRNA levels are 
significantly associated with local recurrence. The mRNA levels of the four enzymes are 
stratified according to the local recurrence. The mRNA expression levels of TP and DPD are 
plotted according to local recurrence. 
 
Figure 3. The level of TS mRNA is significantly correlated with the level of DPD mRNA but 
not with levels of TP and OPRT mRNA. Diagram of the mRNA expression levels of TS, DPD, 
TP and OPRT is scattered. 
 



